|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
|
Fig. 5. (A) Comparison of the ability of Xbh1, Xbh1Vp16 and
Xbh1EngR mRNA to activate the ganglion cell marker Xbrn3d in
animal caps. RT-PCR analysis on animal caps injected with RNA from different
Xbh1 wild-type and fusion constructs, as indicated. Injected amounts
of RNA were 500 pg for each construct, either alone or in combination. (B-E)
Lipofection experiments with Xbh1, Xbh1EngR and Xbh1Vp16
constructs. Embryos were lipofected with GFP+pCS2 vector (C),
GFP+Xbh1 (D), GFP+Xbh1Vp16 (E) or
GFP+Xbh1EngR (not shown), and retinae were analyzed at stage
42. The percent representation of each cell type was calculated as a weighted
average±s.e.m. Counted cells were: n=2625 cells from six
retinae for GFP; n=2908 cells from six retinae for
Xbh1; n=2382 from 15 retinae for Xbh1EngR; and
n=3707 cells from 19 retinae for Xbh1Vp16. Asterisks
represent significant differences as determined by one-way analysis of
variance with the Tukey-Kramer Multiple Comparisons Test as a post-test
(*P<0.05, ***P<0.001).
|
